Overview

  • Product nameAnti-Insulin antibody [INSC7C9]See all Insulin primary antibodies ...
  • Description
    Mouse monoclonal [INSC7C9] to Insulin
  • SpecificityReacts with C-terminal pentapeptide of insulin beta chain.
  • Tested applicationsELISAmore details
  • Species reactivity
    Reacts with: Cow, Human, Pig
  • Immunogen

    Purified human insulin, C-terminal.

Properties

Applications

Our Abpromise guarantee covers the use of ab20371 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
  • Application notesELISA: Use at an assay dependent dilution. Can be used for the detection of insulin in two-site enzyme immunoassay.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionInsulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.
    • Involvement in diseaseDefects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:176730].
      Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
      Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.
      Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
    • Sequence similaritiesBelongs to the insulin family.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • IDDM1 antibody
      • IDDM2 antibody
      • ILPR antibody
      • INS antibody
      • INS_HUMAN antibody
      • Insulin A chain antibody
      • Insulin B chain antibody
      • Insulin precursor antibody
      • IRDN antibody
      • MODY10 antibody
      • Preproinsulin antibody
      • Proinsulin antibody
      • Proinsulin precursor antibody
      see all

    References for Anti-Insulin antibody [INSC7C9] (ab20371)

    ab20371 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab20371.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"